Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations

Journal of Clinical Oncology

Volumn 29, Issue 25, 2011, Pages 3435-3442

  Yuan, Shinsheng ^a   Yu, Sung Liang ^b   Chen, Hsuan Yu ^a   Hsu, Yi Chiung ^a   Su, Kang Yi ^a   Chen, Huei Wen ^b   Chen, Chih Yi ^e   Yu, Chong Jen ^c   Shih, Jin Yuan ^c   Chang, Yih Leong ^b   Cheng, Chiou Ling ^b   Hsu, Chung Ping ^f   Hsia, Jiun Yi ^f   Lin, Chien Yu ^a   Wu, Guani ^a   Liu, Chia Hsin ^a   Wang, Chin Di ^a   Yang, Kang Chung ^a   Chen, Yi Wei ^a   Lai, Yi Ling ^a   Hsu, Chu Chun ^a   Lin, Tai Ching ^b   Yang, Tsung Ying ^g   Chen, Kun Cheieh ^f   Hsu, Kuo Hsuan ^f   Chen, Jeremy J W ^f,g   Chang, Gee Chen ^d,f,g   Li, Ker Chau ^a,h   Yang, Pan Chyr ^b,c   more..

^a INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e China Medical University Hospital   (China)

^f TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^g NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

ADULT; ARTICLE; CANCER TISSUE; CHROMOSOME 7P; CHROMOSOME ABERRATION; CHROMOSOME MUTATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; GENE; GENE CLUSTER; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; WILD TYPE;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 7; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENE DOSAGE; GENOME, HUMAN; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 80052691368     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.3979     Document Type: Article

References (41)

1. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000: The global picture. Eur J Cancer 37:S4-S66, 2001
2. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
3. Herbst RS, Heymach JV, Lippman SM: Lung cancer. N Engl J Med 359:1367-1380, 2008
4. Bogdan S, Klambt C: Epidermal growth factor receptor signaling. Curr Biol 11:R292-R295, 2001 (Pubitemid 32324746)
5. Huang SF, Liu HP, Li LH, et al: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10:8195-8203, 2004
6. Kosaka T, Yatabe Y, Endoh H, et al: Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 64:8919-8923, 2004 (Pubitemid 39665498)
7. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346, 2005 (Pubitemid 40425952)
8. Janne PA, Johnson BE: Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 12:4416s-4420s, 2006 (Pubitemid 44197191)
9. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010
10. Sordella R, Bell DW, Haber DA, et al: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163-1167, 2004 (Pubitemid 39100331)
11. Ono M, Hirata A, Kometani T, et al: Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 3:465-472, 2004 (Pubitemid 39193724)
12. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
13. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004 (Pubitemid 38720929)
14. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004 (Pubitemid 39209661)
15. Inoue A, Suzuki T, Fukuhara T, et al: Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24:3340-3346, 2006 (Pubitemid 46638887)
16. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11:121-128, 2010
17. Mok TS, Wu Y-L, Thongprasert S, et al: Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
18. Yun CH, Boggon TJ, Li Y, et al: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11:217-227, 2007 (Pubitemid 46349842)
19. Chitale D, Gong Y, Taylor BS, et al: An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 28:2773-2783, 2009
20. Kendall J, Liu Q, Bakleh A, et al: Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci U S A 104:16663-16668, 2007 (Pubitemid 350211073)
21. Weir BA, Woo MS, Getz G, et al: Characterizing the cancer genome in lung adenocarcinoma. Nature 450:893-898, 2007 (Pubitemid 350231325)
22. Balsara BR, Sonoda G, Du Manoir S, et al: Comparative genomic hybridization analysis detects frequent, often high-level, overrepresentation of DNA sequences at 3q, 5p, 7p, and 8q in human non-small cell lung carcinomas. Cancer Res 57:2116-2120, 1997 (Pubitemid 27247023)
23. Reinmuth N, Jauch A, Xu EC, et al: Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients. Lung Cancer 62:193-201, 2008
24. Ding L, Getz G, Wheeler DA, et al: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075, 2008
25. Esteller M: Epigenetics in cancer. N Engl J Med 358:1148-1159, 2008
26. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
27. Chang TH, Tsai MF, Su KY, et al: Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med 183:1071-1079, 2010
28. Lu Z, Zhou L, Killela P, et al: Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress. Cancer Res 69:9105-9111, 2009
29. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21:2237-2246, 2003 (Pubitemid 46621858)
30. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003 (Pubitemid 37432975)
31. Mohamed MK, Ramalingam S, Lin Y, et al: Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol 16:780-785, 2005 (Pubitemid 40767100)
32. Perez-Soler R, Chachoua A, Hammond LA, et al: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238-3247, 2004 (Pubitemid 41103678)
33. Shih JY, Gow CH, Yu CJ, et al: Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 118:963-969, 2006
34. Wu YL, Zhou C, Chen G, et al: First biomarker analyses from a phase III, randomised, open-label, first-line study of erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in chinese patients (PTS) with advanced non-small-cell lung cancer (NSCLC) with EGFR activating mutations (OPTIMAL, CTONG 0802). Ann Oncol 21:viii6, 2010 (suppl 8)
35. Wu JY, Wu SG, Yang CH, et al: Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 14:4877-4882, 2008
36. Kawano O, Sasaki H, Endo K, et al: PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 54:209-215, 2006 (Pubitemid 44764916)
37. Sos ML, Koker M, Weir BA, et al: PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 69:3256-3261, 2009
38. Kurita S, Mott JL, Almada LL, et al: GLI3- dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis. Oncogene 29:4848-4858, 2010
39. Chevillard G, Paquet M, Blank V: Nfe2l3 (Nrf3) deficiency predisposes mice to T-cell lymphoblastic lymphoma. Blood 117:2005-2008, 2011
40. Park S, James CD: Lanthionine synthetase components C-like 2 increases cellular sensitivity to adriamycin by decreasing the expression of P-glycoprotein through a transcription-mediated mechanism. Cancer Res 63:723-727, 2003 (Pubitemid 36158153)
41. Baras A, Yu Y, Filtz M, et al: Combined genomic and gene expression microarray profiling identifies ECOP as an upregulated gene in squamous cell carcinomas independent of DNA amplification. Oncogene 28:2919-2924, 2009